European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
A
A
Nast
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
P
P
Gisondi
Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, UK.
A D
AD
Ormerod
Service de Dermatologie, Hôpital Ambroise Paré Université Paris V, Boulogne, France.
P
P
Saiag
Clinical Lead for Dermatology, St Johns Institute of Dermatology, St Thomas' Hospital, London, UK.
C
C
Smith
Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands.
P I
PI
Spuls
Third Faculty of Medicine, Department of Dermatology, Charles University, Prague, Czech Republic.
P
P
Arenberger
Department of Dermatology, Hôpital Saint-Louis, Paris, France.
H
H
Bachelez
St. Johns Institute of Dermatology, St. Thomas' Hospital, London, UK.
J
J
Barker
Hospital Universitario de la Princesa, Madrid, Spain.
E
E
Dauden
University Medical Center Nijmegen St Radboud, Nijmegen, The Netherlands.
E M
EM
de Jong
Medizinische Klinik mit Schwerpunkt Rheumatologie u. klinische Immonologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.
E
E
Feist
Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
A
A
Jacobs
Cambridge, UK.
R
R
Jobling
SZTE Borgyogyaszati Klinika, Szeged, Hungary.
L
L
Kemény
Roma, Italy.
M
M
Maccarone
Department of Dermatology, Psoriasis-Center University Medical Center Schleswig Holstein, Kiel, Germany.
U
U
Mrowietz
Waterloo, Canada.
K A
KA
Papp
Department of Dermatology, Paul Sabatier University, Toulouse, France.
C
C
Paul
Dermatologikum Hamburg, Hamburg, Germany.
K
K
Reich
Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
S
S
Rosumeck
Section of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
T
T
Talme
Department of Dermatology, Erasmus University, Rotterdam, The Netherlands.
H B
HB
Thio
Department of Dermatology, University Hospital Nijmegen, Nijmegen, The Netherlands.
P
P
van de Kerkhof
Division of Evidence Based Medicine, Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
R N
RN
Werner
Department of Dermatology, Inselspital, Universitätsklinik für Dermatologie, Bern, Switzerland.
N
N
Yawalkar
D017255:Acitretin / Q000627:therapeutic use; D000068879:Adalimumab / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept / Q000627:therapeutic use; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007641:Keratolytic Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005650:Fumarates; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D016572:Cyclosporine; D000069549:Ustekinumab; D000068879:Adalimumab; D017255:Acitretin; D000068800:Etanercept; D008727:Methotrexate